Panel: Untangling FDA Requirements for CQAs in IND Applications for Cell Therapy Products

Time: 2:30 pm
day: Cell Therapy Focus Day


• Describing expectations from the FDA on how to maintain CQAs after a method or product change in development of cell therapies

• Avoiding common shortcomings with comparability assessments when presented to FDA regulators

• Applying advice to future development and comparability strategies